Clinical research of DCIK cell combined chemotherapy in treatment of patients with advanced esophageal squamous carcinoma / 中国基层医药

ABSTRACT

Objective To explore the clinical efficacy of dendritic cell activated and cytokine induced killer cell ( DCIK ) combined chemotherapy in treatment of patients with advanced esophageal squamous carcinoma. Methods 60 patients with advanced esophageal squamous carcinoma were selected as the research subjects, they were divided into observation group (32 cases) and control group (28 cases) by random number method.The obser-vation group was given DCIK combined systemic chemotherapy treatment, while the control group was only given chemotherapy.The short-term efficacy,life quality improvement,the immune indexes and the adverse reactions were compared in the two groups 1 month after treatment.Results The short-term efficacy in the observation group was significantly better than the control group(Z=2.807,P<0.05),and the control rate was significantly higher than control group(χ2 =4.133,P<0.05).The life quality in the observation group was significantly better than the control group(Z=2.373,P<0.05),and the effective rate of the observation group was also higher than the control group (χ2 =6.459,P<0.05).The CD3+CD1+8 ,CD3+CD5+6 rates after treatment in the observation group were significantly increased than before treatment (t=7.394,P<0.05),which were significantly higher than the control group(t=-4.564,P<0.05).Conclusion DCIK cell combined chemotherapy not only can improve the immune function in patients with advanced esophageal squamous carcinoma,but also can improve the clinical symptoms and short-term life quality,which has significant clinical application value.